Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) will launch "Dermarin Cool Spray" on January 26, an once-a-day athlete's foot treatment targeting women users.
The active ingredients of "Dermarin Cool Spray" include miconazole nitrate, a compound with an outstanding antifungal action and a strong track record established under the "Dermarin" brand, decalinium chloride, an antibacterial agent that keeps the affected area clean, and lidocaine, which prevents itching. "Dermarin Cool Spray" is both economical and powerful, providing effective relief from a single daily dosage. Each dosage is administered in a controlled spray, which allows for a compact container dispensing up to 400 sprays. The package, a pearl white and pink-base can, has also been designed with women users in mind.
Since 1988, Taisho has worked tirelessly to expand the "Dermarin" series, the first athlete's foot treatment to incorporate the prescription drug miconazole nitrate for use in an OTC drug, developing new product formats such as sprays and modifying initial prescriptions. In March 2003, Taisho released "Dermarin Cool Powder" for women, which has received wide market acceptance and appeal. The launch of "Dermarin Cool Spray" is another step in Taisho's efforts to address the diverse lifestyle needs of its customers.
Product features
| - |
Once-a-day treatment for effective results |
| - |
Aerosol-type spray formulated for a pleasant cool feel |
| - |
Disinfectant agent to help clean the affected area |
| - |
Clear and colorless with no residual powder or coloring |
| - |
Compact container dispensing up to 400 sprays |
Product specification
| Product name |
Dermarin Cool Spray |
| Suggested retail price |
20mL ¥1,800 (plus tax) |
| Ingredients |
(per 20mL)
| Miconazole nitrate |
150mg |
| Decalinium chloride |
15mg |
| Lidocaine |
300mg |
| Dipotassium glycyrrhizinate |
75mg |
| l-menthol |
150mg |
|
| Indications |
Athlete's foot, crotch rot, tinea corporis |
| Dosage |
Apply as required to the affected area, once a day. |
| Date of sale |
January 26, 2004 |
| Expected sales |
¥400 million(one year from date of sale) |
|